Preimplantation Genetic Diagnosis is Fastest Growing Segment Fueling Growth of Preimplantation Genetic Diagnosis Market

Preimplantation Genetic Diagnosis Market:WiseGuyReports.com adds “Global Preimplantation Genetic Diagnosis Market Research Report 2020 Analysis and Forecast 2026” reports to its database.Executive SummaryGlobal Preimplantation Genetic Diagnosis Market is valued approximately USD 407.04 Million in 2019 and is anticipated to grow with a healthy growth rate of more than 10% over the forecast period 2019-2026.

The testing is done when one or both genetic parents has a known genetic abnormality.

Therefore, such test is performed on embryo to identify or determine any genetic abnormality or disorders.

Due to such favorable offering of preimplantation genetic diagnosis people across the globe are adopting such tests, hence increasing awareness among people regarding preimplantation genetic diagnosis coupled with rising incidence of newborn baby with genetic disorders across the globe drives the growth of market over the forecast years.

In Addition, rising number of fertility clinics worldwide are the factors driving the growth of market over the upcoming years.

However, high Procedural cost associated with preimplantation genetic testing is the factor hampers the growth of market.Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/5278138-global-preimplantation-genetic-diagnosis-market-size-study-byThe regional analysis of global Preimplantation Genetic Diagnosis market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World.

Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.The report Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605              The preimplantation genetic screening segment accounted for the largest share of the market in 2016By type, the preimplantation genetic screening segment accounted for the largest share of the market.

The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast periodThe aneuploidy segment is expected to grow at the fastest CAGR.

Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.

Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).North America dominated the market in 2016Geographically, the preimplantation genetic testing market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.

North America accounted for the largest share of the market in 2016, followed by Europe.

Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the preimplantation genetic testing market in North America.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=605As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.

 The global preimplantation genetic testing market is expected to reach USD 107.3 million by 2024, at a CAGR of 6.2% over the forecast period, according to a new report by Grand View Research, Inc.

It is primarily driven by a rising awareness among couples to undergo diagnostic and screening tests to minimize genetic diseases and aneuploidy in fetus.

The ability of preimplantation genetic testing to detect genetic disorders and rare diseases, such as fibrodysplasia ossificans progressive, is anticipated to propel the growth.High adoption of In Vitro Fertilization (IVF) technique consequently upsurges the utilization of Preimplantation Genetic Diagnosis (PGD).

These techniques are advantageous in a way that they allow the development of a healthy fetus and prevent the risk of selective pregnancy termination.

Hence, PGT acts as an addendum to assisted reproductive technology.A substantial number of patients with infertility and impaired fecundity are recommended to embrace IVF therapy in combination with PGT procedures, which in turn is expected to stimulate the growth.

In addition, public and private authorities are promoting reproductive health by undertaking initiatives is also anticipated to drive the Preimplantation Genetic Testing (PGT) (PGS/PGD) market.Further key findings from the report suggest:Availability of a significant number of services related to early diagnosis of specific gene mutation in embryo marked the dominant position of PGD in 2018Preimplantation Genetic Screening (PGS) seems to be reasonable intervention to enhance efficiency of selecting chromosomally normal embryo during IVF cycles.

Autism refers to a brain disorder, which typically affects a child’s ability to communicate, form relationships, and respond appropriately to the environment.

You can get help for autism diagnosis from PanceaPGx, while some people suffering from Autism are relatively high functioning, there are others who are mentally retarded, have serious language delays, or are mute.The actual cause of Autism is not known.

In fact, the early years provide the best time for progress and improvement.

While different children suffering from Autism may have different problems, parents of such children have to face one overwhelming challenge — there is no single agreed upon method for treating this condition.

What makes matters worse is that many children are beset with additional problems like sleeping difficulties, anxiety, or gastrointestinal problems.ABA (Applied Behavioral Analysis)This is often referred to as the Intensive Behavioral Intervention (though there are differences between the two).

Activities begin from simple actions (identifying colors) and progress to more advanced activities (language).

Preimplantation Genetic Testing Market Growth, Trends and Size Analysis by Procedure (Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening), Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, LA Typing and others), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late-Onset Genetic Disorders, Inherited Genetic Disease and others), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Service (Reagents and Consumables, Instruments, Software and Services) - Global Forecast till 2027Market HighlightsIt is estimated that the global preimplantation genetic testing market is expected to register a CAGR of 10.2% during the forecast period of 2019 to 2025, with a market value of USD 375.8 million in 2018.Preimplantation genetic testing is the testing at the pre-implantation stage for detection of genetic defects in embryos or oocytes.

Preimplantation genetic testing has occurred more frequently in recent years in North America and Europe, due to the advancement in genetic technology.The decreasing fertility rates worldwide enhance the acceptance of the preimplantation genetic testing to avoid further complications of chromosomal abnormalities with advancing maternal age.

This leads to the growth of the preimplantation genetic testing market during the forecast period.

According to the Vital Statistics Rapid Release, the total fertility rate for the US in 2017 was 1,764.5 births per 1,000 women, and in 2016 it was 1,820.5,  which is 3% less, this shows the reduction in the rate of fertility.An increasing number of fertility clinics worldwide, new development technological advancements in the field of genetic analysis and high threat of chromosomal abnormalities with advancing maternal age are the other driving factors for global preimplantation genetic testing marketRequest Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8121 SegmentationThe global preimplantation genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS).

The market by end user has been segmented into maternity centers & fertility clinicshospitals, diagnostic labs and research laboratories & academic institutes.

Based on region, the global preimplantation genetic testing market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.Key PlayersSome of the major players in the global preimplantation genetic testing market are Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science LtdRegional AnalysisThe market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Global Preimplantation Genetic Testing Market Research Report: Information by Procedure (Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening), Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, LA Typing and others), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late-Onset Genetic Disorders, Inherited Genetic Disease and others), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Service (Reagents and Consumables, Instruments, Software and Services) - Global Forecast till 2025Market Highlights:It is estimated that the global preimplantation genetic testing market is expected to register a CAGR of 10.2% during the forecast period of 2019 to 2025, with a market value of USD 375.8 million in 2018.Preimplantation genetic testing is the testing at the pre-implantation stage for detection of genetic defects in embryos or oocytes.

Preimplantation genetic testing has occurred more frequently in recent years in North America and Europe, due to the advancement in genetic technology.The decreasing fertility rates worldwide enhance the acceptance of the preimplantation genetic testing to avoid further complications of chromosomal abnormalities with advancing maternal age.

This leads to the growth of the preimplantation genetic testing market during the forecast period.

According to the Vital Statistics Rapid Release, the total fertility rate for the US in 2017 was 1,764.5 births per 1,000 women, and in 2016 it was 1,820.5,  which is 3% less, this shows the reduction in the rate of fertility.An increasing number of fertility clinics worldwide, new development technological advancements in the field of genetic analysis and high threat of chromosomal abnormalities with advancing maternal age are the other driving factors for global preimplantation genetic testing marketAvail a Free Sample@ https://www.marketresearchfuture.com/sample_request/8121 SegmentationThe global preimplantation genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS).

Preimplantation Genetic Screening (PGS) segment is also anticipated to grow profitably to increase healthy pregnancy.By type, embryo testing segment is expected to show favorable growth as the threat of chromosomal abnormalities increases.

The market by end user has been segmented into maternity centers & fertility clinicshospitals, diagnostic labs and research laboratories & academic institutes.

Global Preimplantation Genetic Testing Market Research Report: Information by Procedure (Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening), Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, LA Typing and others), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late-Onset Genetic Disorders, Inherited Genetic Disease and others), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Service (Reagents and Consumables, Instruments, Software and Services) - Global Forecast till 2027Market HighlightsIt is estimated that the global preimplantation genetic testing market is expected to register a CAGR of 10.2% during the forecast period of 2019 to 2025, with a market value of USD 375.8 million in 2018.Preimplantation genetic testing is the testing at the pre-implantation stage for detection of genetic defects in embryos or oocytes.

Preimplantation genetic testing has occurred more frequently in recent years in North America and Europe, due to the advancement in genetic technology.The decreasing fertility rates worldwide enhance the acceptance of the preimplantation genetic testing to avoid further complications of chromosomal abnormalities with advancing maternal age.

This leads to the growth of the preimplantation genetic testing market during the forecast period.

According to the Vital Statistics Rapid Release, the total fertility rate for the US in 2017 was 1,764.5 births per 1,000 women, and in 2016 it was 1,820.5,  which is 3% less, this shows the reduction in the rate of fertility.An increasing number of fertility clinics worldwide, new development technological advancements in the field of genetic analysis and high threat of chromosomal abnormalities with advancing maternal age are the other driving factors for global preimplantation genetic testing marketRequest Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8121SegmentationThe global preimplantation genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS).

The market by end user has been segmented into maternity centers & fertility clinicshospitals, diagnostic labs and research laboratories & academic institutes.

Based on region, the global preimplantation genetic testing market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.Key PlayersSome of the major players in the global preimplantation genetic testing market are Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science LtdRegional AnalysisThe market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

A recent study on the global Preimplantation Genetic Testing market has projected the revenues to rise to the worth of ~US$ 200 million by the end of 2022.

The report highlights the key growth drivers and trends that will contribute to the growth momentum of the market.

The report provides an incisive analysis of the growth dynamics and quantitative assessment of the revenue potential in various regions and across key products, application/end-use industry, and technology segments.

It provides a comprehensive insight into the shares and sizes of the various segments in each year of the forecast period.

A comprehensive evaluation of recent investments by top players in the Preimplantation Genetic Testing market helps identify major research and development initiatives in the key regional markets.

The various assessments on the competitive landscape focus on the intensity of competition, entry barriers, PESTLE analysis, and key winning imperatives.